{"pmid":32425245,"pmcid":"PMC7229965","title":"[Hydroxychloroquine in the treatment of COVID-19: how to use it waiting for conclusive scientific evidence].","text":["[Hydroxychloroquine in the treatment of COVID-19: how to use it waiting for conclusive scientific evidence].","Med Clin (Barc)","Cairoli, Ernesto","Espinosa, Gerard","32425245"],"journal":"Med Clin (Barc)","authors":["Cairoli, Ernesto","Espinosa, Gerard"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425245","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.medcli.2020.05.006","e_drugs":["Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1667252837931810816,"score":9.490897,"similar":[{"pmid":32439730,"title":"Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?","text":["Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?","Postgrad Med J","AlAkhras, Abdullah","AlMessabi, Ahmed Husein","Abuzeid, Hala","Khoo, Saye","Nsutebu, Emmanuel Fru","32439730"],"journal":"Postgrad Med J","authors":["AlAkhras, Abdullah","AlMessabi, Ahmed Husein","Abuzeid, Hala","Khoo, Saye","Nsutebu, Emmanuel Fru"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32439730","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/postgradmedj-2020-137990","keywords":["infectious diseases","therapeutics"],"topics":["Treatment"],"weight":1,"_version_":1667523504821501952,"score":46.0626},{"pmid":32304156,"title":"Inaccurate conclusions by Tang and colleagues.","text":["Inaccurate conclusions by Tang and colleagues.","I read with interest the study by Tang and colleagues, published March 27, 2020, entitled \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease patients with coagulopathy.\" Unfortunately, this retrospective study came to conclusions that are inaccurate with the information provided. The authors use of the word \"therapy\" implies that patients were given therapeutic doses of anticoagulants, however, doses appear to be most consistent with prophylaxis dosing. The authors report that 94 patients received enoxaparin at 40-60mg/day. They did not specify the route of administration, subcutaneous (SC) or intravenous (IV), nor did they specify the percentage of patients that received which dose. The 40mg per day dose of enoxaparin given SC is the prophylactic dose. The 60mg per day IV dose would be therapeutic for patients weighing 40kg, not a typical weight for an adult patient.","J Thromb Haemost","Greenstein, Yonatan Y","32304156"],"abstract":["I read with interest the study by Tang and colleagues, published March 27, 2020, entitled \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease patients with coagulopathy.\" Unfortunately, this retrospective study came to conclusions that are inaccurate with the information provided. The authors use of the word \"therapy\" implies that patients were given therapeutic doses of anticoagulants, however, doses appear to be most consistent with prophylaxis dosing. The authors report that 94 patients received enoxaparin at 40-60mg/day. They did not specify the route of administration, subcutaneous (SC) or intravenous (IV), nor did they specify the percentage of patients that received which dose. The 40mg per day dose of enoxaparin given SC is the prophylactic dose. The 60mg per day IV dose would be therapeutic for patients weighing 40kg, not a typical weight for an adult patient."],"journal":"J Thromb Haemost","authors":["Greenstein, Yonatan Y"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304156","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14857","e_drugs":["Enoxaparin"],"topics":["Treatment"],"weight":1,"_version_":1666138491134672896,"score":44.59207},{"pmid":32459574,"title":"The world is waiting, use sequential analysis and get us the evidence-based treatment we need for COVID-19.","text":["The world is waiting, use sequential analysis and get us the evidence-based treatment we need for COVID-19.","In spite of the relatively high morbidity and mortality, there is no approved medication yet for COVID-19. There are more than 200 ongoing trials on different drugs or vaccines, but new medications may take until 2021 to develop. Defining the optimal number of patients to be included in a study is a considerable challenge in these interventional researches. Ethical considerations prompt researchers to minimize the number of patients included in a trial. This gains particular importance when the disease is rare or lethal which is particularly so in the case of COVID-19. It is of paramount importance to explore some of the available tools that could help accelerate the adoption of any or some of the many proposed modalities for the treatment of diseases. These tools should be effective, yet efficient, for rapid testing of such treatments. Sequential analysis has not been frequently used in many clinical trials where it should have been used. None of the authors in published literature, as far as we know, used sequential analysis techniques to test potential drugs for COVID-19. In addition to its usefulness when the results of new forms of treatment are quickly needed, other important benefit of sequential analysis includes the ability to reach a similar conclusion about the utility of a new drug without unduly exposing more patients to the side effect of the old drug, in particularly, for the treatment of a rare disease.","Libyan J Med","El Taguri, Adel","Nasef, Aisha","32459574"],"abstract":["In spite of the relatively high morbidity and mortality, there is no approved medication yet for COVID-19. There are more than 200 ongoing trials on different drugs or vaccines, but new medications may take until 2021 to develop. Defining the optimal number of patients to be included in a study is a considerable challenge in these interventional researches. Ethical considerations prompt researchers to minimize the number of patients included in a trial. This gains particular importance when the disease is rare or lethal which is particularly so in the case of COVID-19. It is of paramount importance to explore some of the available tools that could help accelerate the adoption of any or some of the many proposed modalities for the treatment of diseases. These tools should be effective, yet efficient, for rapid testing of such treatments. Sequential analysis has not been frequently used in many clinical trials where it should have been used. None of the authors in published literature, as far as we know, used sequential analysis techniques to test potential drugs for COVID-19. In addition to its usefulness when the results of new forms of treatment are quickly needed, other important benefit of sequential analysis includes the ability to reach a similar conclusion about the utility of a new drug without unduly exposing more patients to the side effect of the old drug, in particularly, for the treatment of a rare disease."],"journal":"Libyan J Med","authors":["El Taguri, Adel","Nasef, Aisha"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459574","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/19932820.2020.1770518","keywords":["covid-19","sequential analysis","clinical trials","treatment"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667967699014123521,"score":44.334064},{"pmid":32324223,"pmcid":"PMC7188138","title":"Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence.","text":["Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence.","Eur Heart J","Kuster, Gabriela M","Osswald, Stefan","32324223"],"journal":"Eur Heart J","authors":["Kuster, Gabriela M","Osswald, Stefan"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324223","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1093/eurheartj/ehaa335","topics":["Treatment"],"weight":1,"_version_":1666138493856776193,"score":42.268658}]}